Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

NCT04256941 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Despite modifications, accrual was poor and the closed

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Breast Carcinoma
Prognostic Stage IV Breast Cancer AJCC v8

Interventions

DRUG: Abemaciclib
DRUG: Anastrozole
DRUG: Fulvestrant
DRUG: Letrozole
DRUG: Palbociclib
DRUG: Ribociclib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]